Details

Autor(en) / Beteiligte

• Tormo, N
• Solano, C
• Benet, I
• Clari, M A
• Nieto, J
• de la Camara, R
• Lopez, J
• Lopez-Aldeguer, N
• Hernandez-Boluda, J C
• Remigia, M J
• Garcia-Noblejas, A
• Gimeno, C
• Navarro, D

Titel

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNg CD8 super(+) and CD4 super(+) T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2010-03, Vol.45 (3), p.543-549

Erscheinungsjahr

2010

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Rising levels of cytomegalovirus (CMV) DNAemia and/or pp65 antigenemia have been observed during pre-emptive ganciclovir therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). We assessed the incidence of this event in our series, and investigated whether its occurrence was associated with an impairment in the CMV-specific T-cell response. A total of 36 allo-SCT recipients experienced one or more episodes of active CMV infection (n=68) that were pre-emptively treated with val(ganciclovir). Rising levels of antigenemia and DNAemia, and an isolated increase in antigenemia, were observed in 39.7 and 2.9% of all episodes, respectively. Receipt of corticosteroids was associated with rising levels of antigenemia and DNAemia. Median increases of 12- and 6.8-fold of IFNg CD8 super(+) T and IFNg CD4 super(+) T cells, respectively, were observed at a median of 16.5 days after initiation of therapy in episodes with decreasing levels in antigenemia and DNAemia. In contrast, the numbers of both T-cell subsets at a median of 13.5 days after initiation of therapy did not differ significantly from those of pre-treatment samples in episodes with rising levels of antigenemia and DNAemia. Lack of prompt expansion of CMV pp65 and IE-1-specific IFNg CD8 super(+) and CD4 super(+) T cells is associated with rising levels in antigenemia and DNAemia during pre-emptive therapy.